Status: In Pennsylvania, qualified patients may possess and use medical marijuana. State licensed businesses may grow, process, transport, and dispense medical marijuana.
|CBD Program||Medical Program||Recreational Program||Are Applications Open?|
Number of Pennsylvania Licenses Available
Pennsylvania Medical Marijuana Growers/Processors Guidelines
- Allows for no more than 25 permits
- Not more than 1 Grower permit shall be awarded to an applicant
- Not more than 5 Growers may be issued dispensary permits as well
- Must be an in door grow facility
- Initial nonrefundable application fee of $10,000.
- A fee of $200,000 must be submitted with application and will be returned if the permit is not granted.
- Annual renewal fee of $10,000
- Proof of funds of $2 Million, $500,000 of which must be deposited in the applicant’s bank account
Pennsylvania Medical Marijuana Dispensary Guidelines
- Not more than 50 dispensary permits to be awarded.
- No more than 5 permits to be awarded to one person.
- Each permit holder will be allowed to open up to 3 dispensaries.
- Initial nonrefundable application fee of $5,000.
- A fee of $30,000 for each location, must be submitted with the application and will be returned if the permit is not granted.
- Annual renewal fee of $5,000.
- Proof of funds of $150,000 must be deposited in applicant’s bank account
The History of Pennsylvania Marijuana
Senate Bill 3, a bill that provides for the medical use of cannabis in the Commonwealth of Pennsylvania, was signed into law (Act 16) on April 17th, 2016. The Act allows for the consumption and possession of medical marijuana for patients suffering from qualified medical conditions. It also allows for a state regulated dispensary system to grow and sell cannabis. The Medical Marijuana Advisory Board within the Department of Health has been tasked to regulate the program. The entire Act 16 can be found here.
Qualifying Medical Conditions: Amyotrophic Lateral Sclerosis, Autism, Cancer, Crohn’s Disease, Damage to the nervous tissue of the spinal cord with objective neurological indication of intractable spasticity, Epilepsy, Glaucoma, HIV/AIDS, Huntington’s Disease, Inflammatory Bowel Disease, Intractable Seizures, Multiple Sclerosis, Neuropathies (nerve damage), Parkinson’s Disease, PTSD, Severe chronic or intractable pain of neuropathic origin or severe chronic or intractable pain in which conventional therapeutic intervention and opiate therapy is contraindicated or ineffective, Sickle Cell Anemia
On March 20, 2017 the state closed Phase 1 of the application process for Medical Marijuana Business Licenses. The state has not yet released a date for when Phase 2 will begin, but it is anticipated to sometime in the first quarter of 2018.